

Bangkok Dusit Medical

Bangkok Dusit Medical Services
Public Company Limited

BDMS

Bloomberg BDMS TB
Reuters BDMS.BK



Preview 4Q23: Fueled by strong revenue

Although BDMS share price has risen 5%, beating the SET's drop of 3% over the past month, valuation remains undemanding at 29x 2024PE, below -2SD of historical average. We expect price to continue to outperform on optimism over its healthy earnings. We estimate BDMS' core profit in 4Q23 at Bt3.6bn (up 16% YoY but down 7% QoQ) and forecast core earnings growth of 8% in 2024. We maintain Outperform with end-2024 DCF TP of Bt35/share. BDMS is one of our top picks in the Healthcare Service sector.

Preview 4Q23: Up YoY on strong revenue but down QoQ on seasonality. We estimate 4Q23 core profit at Bt3.6bn, up 16% YoY but down 7% QoQ, with the YoY growth driven by strong revenue and the QoQ drop seasonal. We estimate 4Q23 revenue at Bt24.8bn (+10% YoY, -3% QoQ), backed by higher growth in international patient services (+15% YoY, +6% QoQ, 28% of 4Q23's revenue) than in Thai patient services (+8% YoY, -6% QoQ on seasonality, 72% of 4Q23's revenue). The primary international markets (the Middle East at 4% of revenue and China at 2%) continue doing well but the concern on unrest in Myanmar (2% of revenue) is expected to bring slow growth. We estimate EBITDA margin at 23.8% in 4Q23, flat YoY but down QoQ due to seasonally lower revenue and higher expenses. Our 4Q23 preview suggests our 2023F is achievable and we maintain our forecast. It will release results on February 21.

Earnings growth back to normal in 2024. In 2024, we estimate core earnings growth of 8% to Bt15bn, underwritten by 6% revenue growth and wider EBITDA margin (24.9% from 24.5% in 2023) from growing international patient services, rising revenue from the high-margin Centers of Excellence and better asset utilization through enlarging the private insurance segment (36% of revenue) and growing social security scheme services (SC, 2% of revenue). Currently, BDMS has 11 hospitals providing SC services with a quota of 1mn and registered persons of ~800K. Recently, its SC quota was increased to 1.5mn, which will allow it to serve more SC registered patients; it targets 1mn in 2025.

Undemanding valuation. BDMS is trading at 29x 2024PE, below -2SD of its historical average of 32x (since 2015, excluding the COVID-19 years of 2020-21). We stay positive on its sound fundamentals, with healthy earnings and long-term growth potential from growing healthcare demand in the EEC area. We maintain our 3-month tactical call of Outperform with end-2024 DCF TP of Bt35/share (WACC at 7.1% and LT growth at 3%).

Risks. We are keeping an eye on the global economic slowdown and geopolitical risk that may cause clients to delay elective medical care and make it inconvenient for international patients to come to Thailand for treatment. We see ESG risk as patient safety (S): BDMS has adopted a variety of quality assurance systems to provide continuous patient care.

Forecasts and valuation

Year to 31 Dec	Unit	2021	2022	2023F	2024F	2025F
Revenue	(Btmn)	71,541	88,535	95,231	101,118	107,125
EBITDA	(Btmn)	17,622	23,021	24,593	26,579	28,201
Core profit	(Btmn)	7,736	12,606	14,172	15,292	16,540
Reported profit	(Btmn)	7,936	12,606	14,172	15,292	16,540
Core EPS	(Bt)	0.49	0.79	0.89	0.96	1.04
DPS	(Bt)	0.45	0.60	0.60	0.60	0.68
P/E, core	(x)	56.5	34.7	30.8	28.6	26.4
EPS growth, core	(%)	26.9	63.0	12.4	7.9	8.2
P/BV, core	(x)	5.2	4.9	4.6	4.4	4.1
ROE	(%)	8.6	13.9	14.7	15.1	15.4
Dividend yield	(%)	1.6	2.2	2.2	2.2	2.5
EV/EBITDA	(x)	25.1	19.2	17.6	16.1	14.9
EBITDA growth	(%)	17.6	30.6	6.8	8.1	6.1

Source: InnovestX Research

Tactical: OUTPERFORM (3-month)

Stock data

Last close (Jan 22) (Bt)	27.50
Target price (Bt)	35.00
Mkt cap (Btbn)	437.03
Mkt cap (US\$m)	12,280

Beta	L
Mkt cap (%) SET	2.59
Sector % SET	5.61
Shares issued (mn)	15,892
Par value (Bt)	0.10
12-m high / low (Bt)	30.8 / 25
Avg. daily 6m (US\$m)	33.90
Foreign limit / actual (%)	30 / 26
Free float (%)	69.8
Dividend policy (%)	≥ 50

Share performance

(%)	1M	3M	12M
Absolute	4.8	1.9	(8.3)
Relative to SET	7.5	4.0	12.7

Source: SET, InnovestX Research

2023 Sustainability/2022 ESG Score

SET ESG Ratings	AA
-----------------	----

ESG Bloomberg Rank in the sector

ESG Score Rank	1/22
Environmental Score Rank	1/22
Social Score Rank	2/22
Governance Score Rank	2/22

ESG comment

BDMS has the highest ESG score in the sector and it is clear on its focus on sustainability with committed targets for environment, social, and governance criteria
Source: Bloomberg Finance L.P.

Analyst

Raweenuch Piyakriengkai

Fundamental Investment
Analyst on Securities
(66-2) 949-1002
raweenuch.piyakriengkai@scb.co.th

Value proposition

BDMS is Thailand's largest private hospital operator (57 hospitals with over 8,500 beds) and is one of the top five private hospital operators in the world by market capitalization. BDMS is placing itself to get in on rising demand for quality healthcare and to provide the entire spectrum of healthcare service, from preventive (wellness business) to curative and rehabilitative.

Business outlook

In 2024, we estimate BDMS core earnings at Bt15bn, growing 8%, based on 6% revenue growth and a wider EBITDA margin (24.9% from 24.5% in 2023) from growing international patient services, rising revenue from Centers of Excellence (providing a high EBITDA margin) and better asset utilization through enlarging the private insurance segment and increasing patients covered by the social security scheme.

Private hospitals are focusing on the EEC area (Chonburi, Rayong and Chachoengsao), where demand for healthcare is increasing in tandem with economic activities. BDMS has the strongest presence in EEC with 10 hospitals and is expanding. In Chonburi, BDMS plans to add more beds at *Bangkok Hospital Pattaya* and *Jomtien Hospital* (from 400 to ~600 beds). It plans to open a new hospital, *Phayathai Bowin Hospital*, in 2025. This will be 220-bed greenfield hospital with the first phase of 59 beds. In Rayong, BDMS plans to bring beds up to ~600 from 374 beds.

Besides the bed expansion, BDMS has actively expanded into non-hospital businesses including digital health services, setting up the Genomic Center and investing in *BDMS Silver Wellness & Residence*, a mixed-use project (clinic, hotel and residential) for the wellness business. Although the non-hospital businesses are still small at 4-5% of revenue, BDMS sees opportunity for growth from broadening its scope of services and expects revenue from non-hospital businesses to reach 20% of revenue in the future.

Bullish views	Bearish views
1. Sound fundamentals, providing the entire spectrum of healthcare, from preventive (wellness business) to curative and rehabilitative. 2. Strong financial health	1. Concern about competition.

Key catalysts

Factor	Event	Impact	Comment
Near-term earnings outlook	4Q23F earnings momentum	+YoY and -QoQ	We estimate core profit in 4Q23 at Bt3.6bn, up 16% YoY but down 7% QoQ due to seasonality.
Near-term earnings outlook	1Q24F earnings momentum	+YoY and +QoQ	We expect core profit in 1Q24 to grow YoY with revenue growth as a key driver and grow QoQ due to seasonality.
Factors to be aware of in 2024	Potential growth in EEC	Positive	We are positive toward the health demand in EEC and because of the area's low bed supply, do not expect a significant impact from intense competition. BDMS has the strongest presence in EEC with 10 hospitals and is expanding.
Factors to be aware of in 2024	Global economic slowdown and geopolitical risk	Negative	Revenue from international patient services has recovered to above pre-COVID-19 level, accounting for 27% of 9M23's revenue. We are keeping an eye on the global economic slowdown and geopolitical risk that may cause delays in elective medical care and make it inconvenient for international patients to seek treatment abroad.

Sensitivity analysis

Factor	Earnings impact	TP impact
1ppt change in hospital revenue	2-3%	Bt0.7/share (2%)

Our view on ESG

BDMS is clear on its focus on sustainability with committed targets for environment, social, and governance criteria through material process and procedure, setting out a strategy and guidelines for all stakeholders and reviewing risks covering current and future healthcare business.

ESG Disclosure Score

Bloomberg ESG Score	58.92 (2022)	CG Rating	DJSI	SETESG	SET ESG Ratings	
Rank in Sector	1/22	BDMS	5	Yes	Yes	AA

Source: Thai Institute of Directors (IOD), SET

Environmental Issue (E)

- BDMS intends to accomplish net zero emissions in 2050. BDMS has adopted circular economy principles on energy and resources management. In addition, BDMS plans to improve energy efficiency and ensure that the least impact by business activities on the environment in the design process, management, clean energy and high-efficiency equipment and technology.
- BDMS has set direction and sustainability goals in 2050 to increase the recycling of non-hazardous waste to 50% while promoting plastic container recycling and the use of biodegradable containers.
- BDMS targets reducing water consumption per baht revenue vs. 2022, its base year. It is determined to improve water management throughout the supply chain by constantly developing the process, technology, innovation and fundamental structure.

Social Issue (S)

- BDMS enforces policies regarding staff health, safety and biohazard post-exposure management to ensure the work readiness of employees and contractors in the hospitals.
- BDMS organizes training and development for clinical and non-clinical employees, including newly-recruited, contracted and part-time employees.
- BDMS assigns related departments to collaborate in building community engagement through data surveys and understanding the community's expectations. In 2022, it put out 804 initiatives on preventive healthcare and health literacy for communities in Thailand.
- We see ESG risk for healthcare service sector as patient safety and BDMS has adopted a variety of quality assurance systems to provide continuous patient care.

Governance Issue (G)

- BDMS Board of Directors establishes the corporate governance policy for executives, committees and employees as operational guidelines.
- BDMS appointed a standardization and compliance committee to ensure all subsidiary hospitals operate in line with quality policies, patient safety plan and corporate strategy.
- BDMS has a patient experience management working team to systematically manage customer relations. The satisfaction survey rates in 2022 increased or presented at 92% vs target of 86%, putting its score in the 95th percentile compared with 4,442 hospitals in the USA as reported by HCAHPS Score.
- As of December 31, 2022, there were 17 directors in total, consisting of 8 executive directors (47.06% of all directors), 2 non-executive directors (11.76% percent of all directors) and 7 independent directors (41.18% percent of all directors). We view the structure is appropriate as independent directors are not less than one-third of the Board of Director and
- The chairman is an independent director
- Major shareholders control ~20% of total issued and paid-up shares.

ESG Disclosure Score

	2021	2022
ESG Disclosure Score	58.34	58.92
Environment	54.27	56.00
Emissions Reduction Initiatives	No	No
Climate Change Policy	Yes	Yes
GHG Scope 1 ('000 metric tonnes)	8.67	33.69
GHG Scope 2 Location-Based ('000 metric tonnes)	95.94	208.85
Energy Efficiency Policy	Yes	Yes
Total Energy Consumption ('000 metric tonnes)	194.45	497.08
Waste Reduction Policy	Yes	Yes
Total Waste ('000 metric tonnes)	9.05	13.23
Water Policy	Yes	Yes
Total Water Withdrawal ('000 cubic meters)	249.84	435.79
Social	37.06	37.06
Human Rights Policy	Yes	Yes
Consumer Data Protection Policy	Yes	Yes
Pct Women in Workforce (%)	82.63	82.75
Last Time Incident Rate - Employees (per 100 employees)	0.00	0.98
Number of Employees - CSR (persons)	36,880	40,495
Total Hours Spent by Firm - Employee Training (hours)	437,209	1,417,320
Governance	83.59	83.59
Size of the Board (persons)	18	17
Board Meeting Attendance Pct (%)	97	100
Number of Independent Directors (persons)	7	7
% Independent directors to total board members	39	41
Board Duration (Years)	3	3

Source: Bloomberg Finance L.P.

Disclaimer

Bloomberg ESG Disclosure Scores rate companies on their level of disclosure of ESG data. Bloomberg offers four disclosure scores, for overall ESG, as well as Environmental, Social, and Governance. To review the fully transparent methodology, calculate disclosure scores for any company, and compare a company's scores vs its peers, see ESG Disclosure Score Model in Bloomberg.

Financial statement Profit and Loss Statement

FY December 31	Unit	2018	2019	2020	2021	2022	2023F	2024F	2025F
Total revenue	(Btmn)	75,331	79,630	65,166	71,541	88,535	95,231	101,118	107,125
Cost of goods sold	(Btmn)	51,546	54,277	46,371	49,462	58,329	63,045	67,112	71,249
Gross profit	(Btmn)	23,784	25,354	18,795	22,079	30,205	32,185	34,007	35,876
SG&A	(Btmn)	15,998	17,447	14,161	15,029	17,655	18,566	19,330	20,126
Other income	(Btmn)	4,803	11,882	5,187	4,050	4,521	5,238	5,562	5,892
Interest expense	(Btmn)	1,165	929	871	728	632	572	512	312
Pre-tax profit	(Btmn)	11,424	18,860	8,950	10,373	16,440	18,285	19,726	21,330
Corporate tax	(Btmn)	2,740	3,873	2,751	2,103	3,227	3,657	3,945	4,266
Equity a/c profits	(Btmn)	1,690	1,022	273	21	42	44	46	48
Minority interests	(Btmn)	(456)	(492)	(435)	(554)	(648)	(500)	(535)	(572)
Core profit	(Btmn)	9,918	9,560	6,037	7,736	12,606	14,172	15,292	16,540
Extra-ordinary items	(Btmn)	(727)	5,957	1,177	200	0	0	0	0
Net Profit	(Btmn)	9,191	15,517	7,214	7,936	12,606	14,172	15,292	16,540
EBITDA	(Btmn)	17,249	18,032	14,982	17,622	23,021	24,593	26,579	28,201
Core EPS (Bt)	(Btmn)	0.64	0.61	0.38	0.49	0.79	0.89	0.96	1.04
Net EPS (Bt)	(Bt)	0.59	0.99	0.46	0.50	0.79	0.89	0.96	1.04
DPS (Bt)	(Bt)	0.32	0.55	0.55	0.45	0.60	0.60	0.60	0.68

Balance Sheet

FY December 31	Unit	2018	2019	2020	2021	2022	2023F	2024F	2025F
Total current assets	(Btmn)	15,198	16,325	30,013	24,401	27,799	20,835	23,058	30,278
Total fixed assets	(Btmn)	74,496	78,440	81,313	79,689	81,860	81,238	80,705	80,254
Total assets	(Btmn)	133,499	133,662	136,050	128,454	141,543	133,535	134,804	141,152
Total loans	(Btmn)	39,849	24,316	20,701	15,672	15,998	4,998	0	0
Total current liabilities	(Btmn)	28,499	19,263	11,220	15,862	20,616	13,357	13,748	14,185
Total long-term liabilities	(Btmn)	29,790	24,099	20,594	15,596	15,498	4,998	0	0
Total liabilities	(Btmn)	60,061	46,480	44,588	40,689	47,830	35,070	30,464	30,901
Paid-up capital	(Btmn)	1,567	1,589	1,589	1,589	1,589	1,589	1,589	1,589
Total equity	(Btmn)	73,438	87,182	91,463	87,765	93,713	98,465	104,340	110,251
BVPS (Bt)	(Bt)	4.50	5.33	5.59	5.28	5.66	5.95	6.31	6.67

Cash Flow Statement

FY December 31	Unit	2018	2019	2020	2021	2022	2023F	2024F	2025F
Core Profit	(Btmn)	9,918	9,560	6,037	7,736	12,606	14,172	15,292	16,540
Depreciation and amortization	(Btmn)	5,386	5,752	6,413	6,321	5,950	5,735	6,341	6,559
Operating cash flow	(Btmn)	14,804	14,546	11,681	14,561	20,266	18,877	20,910	22,392
Investing cash flow	(Btmn)	(13,351)	2,818	12,385	(4,763)	(5,901)	(4,762)	(5,056)	(5,356)
Financing cash flow	(Btmn)	(1,511)	(17,701)	(9,096)	(18,531)	(12,631)	(20,984)	(14,414)	(10,629)
Net cash flow	(Btmn)	(58)	(337)	14,970	(8,733)	(8,733)	(6,869)	1,440	6,407

Key Financial Ratios

FY December 31	Unit	2018	2019	2020	2021	2022	2023F	2024F	2025F
Gross margin	(%)	31.6	31.8	28.8	30.9	34.1	33.8	33.6	33.5
Operating margin	(%)	10.3	9.9	7.1	9.9	14.2	14.3	14.5	14.7
EBITDA margin	(%)	21.7	21.5	21.7	23.3	24.7	24.5	24.9	25.0
EBIT margin	(%)	15.7	24.9	16.9	15.8	19.3	19.8	20.0	20.2
Net profit margin	(%)	12.2	19.5	11.1	11.1	14.2	14.9	15.1	15.4
ROE	(%)	14.2	11.9	6.8	8.6	13.9	14.7	15.1	15.4
ROA	(%)	7.7	7.2	4.5	5.8	9.3	10.3	11.4	12.0
Net D/E	(x)	0.5	0.3	(0.0)	0.1	0.1	(0.0)	(0.1)	(0.1)
Interest coverage	(x)	14.8	19.4	17.2	24.2	36.4	43.0	51.9	90.4
Debt service coverage	(x)	1.1	2.9	15.3	4.5	3.8	43.0	51.9	90.4
Payout Ratio	(%)	54	55.8	120.0	90.1	75.6	67.3	62.4	65.0

Main Assumptions

FY December 31	Unit	2018	2019	2020	2021	2022	2023F	2024F	2025F
Revenue by nationality									
International	(%)	30.0	30.0	21.0	18.0	24.0	28.6	30.2	31.9
Thai	(%)	70.0	70.0	79.0	82.0	76.0	71.4	69.8	68.1

Financial statement

Profit and Loss Statement

FY December 31	Unit	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23
Total revenue	(Btmn)	20,914	22,165	20,976	22,825	22,568	23,084	23,141	25,473
Cost of goods sold	(Btmn)	13,525	14,451	14,147	14,979	14,752	15,122	15,432	16,469
Gross profit	(Btmn)	7,389	7,714	6,829	7,846	7,816	7,962	7,709	9,003
SG&A	(Btmn)	4,691	4,025	4,200	4,496	4,933	4,633	4,876	5,106
Other income	(Btmn)	978	1,007	1,030	1,179	1,306	1,267	1,285	1,282
Interest expense	(Btmn)	173	158	151	154	169	164	134	122
Pre-tax profit	(Btmn)	3,503	4,538	3,508	4,374	4,020	4,432	3,983	5,057
Corporate tax	(Btmn)	746	903	695	824	806	880	812	1,025
Equity a/c profits	(Btmn)	10	9	7	16	10	34	13	21
Minority interests	(Btmn)	(131)	(201)	(155)	(181)	(111)	(116)	(120)	(163)
Core profit	(Btmn)	2,636	3,443	2,664	3,386	3,113	3,470	3,063	3,890
Extra-ordinary items	(Btmn)	0	0	0	0	0	0	0	0
Net Profit	(Btmn)	2,636	3,443	2,664	3,386	3,113	3,470	3,063	3,890
EBITDA	(Btmn)	5,232	6,186	5,144	6,018	5,673	6,025	5,563	6,649
Core EPS (Bt)	(Btmn)	0.17	0.22	0.17	0.21	0.20	0.22	0.19	0.24
Net EPS (Bt)	(Bt)	0.17	0.22	0.17	0.21	0.20	0.22	0.19	0.24

Balance Sheet

FY December 31	Unit	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23
Total current assets	(Btmn)	24,401	27,176	30,255	27,074	27,799	30,419	23,705	23,295
Total fixed assets	(Btmn)	79,689	79,506	79,190	79,490	81,860	82,002	82,695	83,919
Total assets	(Btmn)	128,454	131,098	133,780	133,875	141,543	144,509	138,662	139,893
Total loans	(Btmn)	15,672	13,096	16,097	15,997	15,998	14,498	10,498	12,498
Total current liabilities	(Btmn)	15,862	18,887	22,801	22,966	20,616	21,941	18,477	20,732
Total long-term liabilities	(Btmn)	15,596	13,096	13,097	13,497	15,498	11,498	9,498	9,498
Total liabilities	(Btmn)	40,689	39,802	42,817	43,586	47,830	47,928	43,610	46,278
Paid-up capital	(Btmn)	1,589	1,589	1,589	1,589	1,589	1,589	1,589	1,589
Total equity	(Btmn)	87,765	91,296	90,962	90,289	93,713	96,581	95,051	93,614
BVPS (Bt)	(Bt)	5.28	5.49	5.47	5.41	5.66	5.88	5.78	5.67

Cash Flow Statement

FY December 31	Unit	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23
Core Profit	(Btmn)	2,636	3,443	2,664	3,386	3,113	3,470	3,063	3,890
Depreciation and amortization	(Btmn)	1,556	1,490	1,486	1,490	1,484	1,429	1,446	1,470
Operating cash flow	(Btmn)	5,198	5,147	4,382	3,660	7,077	6,005	5,476	5,346
Investing cash flow	(Btmn)	(1,355)	(2,145)	(1,256)	(1,966)	(535)	(508)	(1,857)	(3,134)
Financing cash flow	(Btmn)	(4,105)	(2,636)	(547)	(4,980)	(4,468)	(1,679)	(9,662)	(4,440)
Net cash flow	(Btmn)	(262)	366	2,579	(3,285)	2,075	3,817	(6,043)	(2,227)

Key Financial Ratios

FY December 31	Unit	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23
Gross margin	(%)	35.3	34.8	32.6	34.4	34.6	34.5	33.3	35.3
Operating margin	(%)	12.9	16.6	12.5	14.7	12.8	14.4	12.2	15.3
EBITDA margin	(%)	23.9	26.7	23.4	25.1	23.8	24.7	22.8	24.9
EBIT margin	(%)	17.6	21.2	17.4	19.8	18.6	19.9	17.8	20.3
Net profit margin	(%)	12.6	15.5	12.7	14.8	13.8	15.0	13.2	15.3
ROE	(%)	8.6	15.0	13.8	14.5	13.9	14.8	14.0	15.1
ROA	(%)	5.8	10.3	9.5	9.6	9.3	10.1	9.6	10.2
Net D/E	(x)	0.1	0.0	0.1	0.1	0.1	(0.0)	0.0	0.0
Interest coverage	(x)	30.3	39.1	34.0	39.1	33.6	36.7	41.5	54.4
Debt service coverage	(x)	5.4	4.7	2.2	3.0	3.7	3.9	7.3	5.3

Main Assumptions



FY December 31	Unit	4Q21	1Q22	2Q22	3Q22	4Q22	1Q23	2Q23	3Q23
Revenue by nationality									
International	(%)	18.0	22.0	24.0	24.0	27.0	29.5	26.0	26.0
Thai	(%)	82.0	78.0	76.0	76.0	73.0	70.5	74.0	74.0

Figure 1: BDMS's earnings preview in 4Q23

(Bt mn)	4Q22	1Q23	2Q23	3Q23	4Q23F	YoY%	QoQ%
Revenue	22,568	23,084	23,141	25,473	24,833	10.0	(2.5)
Gross profit	7,816	7,962	7,709	9,003	7,331	(6.2)	(18.6)
EBITDA	5,673	6,025	5,563	6,649	6,255	10.3	(5.9)
Core profit	3,113	3,470	3,063	3,890	3,604	15.7	(7.4)
Net profit	3,113	3,470	3,063	3,890	3,604	15.7	(7.4)
EPS (Bt/share)	0.20	0.22	0.19	0.24	0.23	15.7	(7.4)
Financial Ratio							
Gross Margin (%)	34.6	34.5	33.3	35.3	29.5	(5.1)	(5.8)
EBITDA margin (%)	23.8	24.7	22.8	24.9	23.8	0.1	(1.0)
Net Profit Margin (%)	13.8	15.0	13.2	15.3	14.5	0.7	(0.8)
(Bt mn)	4Q22	1Q23	2Q23	3Q23	4Q23F	% YoY	% QoQ
Revenue by nationality							
Thai	16,475	16,274	17,124	18,850	17,793	8.0	(5.6)
International patients	6,093	6,810	6,017	6,623	7,040	15.5	6.3
Total revenue	22,568	23,084	23,141	25,473	24,833	10.0	(2.5)

Source: Company data and InnovestX Research


Figure 2: BDMS' earnings forecast



Source: InnovestX Research


Source: InnovestX Research

Figure 3: BDMS' revenue breakdown by nationality



Source: BDMS and InnovestX Research

Figure 4: BDMS' valuation is undemanding, trading below -2SD of its historical average.



Source: SET and InnovestX Research
PE band since 2015, excluding 2020-21 which is an exceptional COVID-19 period

Figure 5: Valuation summary (price as of Jan 22, 2024)

	Rating	Price (Bt/Sh)	Target (Bt/Sh)	ETR (%)	P/E (x)			EPS growth (%)			P/BV (x)			ROE (%)			Div. Yield (%)			EV/EBITDA (x)		
					22A	23F	24F	22A	23F	24F	22A	23F	24F	22A	23F	24F	22A	23F	24F	22A	23F	24F
BCH	Outperform	22.90	24.0	6.1	14.1	38.6	32.7	(40.8)	(63.5)	18.2	4.6	4.3	4.1	29	11	12	3.5	1.3	1.5	11.3	19.3	16.8
BDMS	Outperform	27.50	35.0	29.5	34.7	30.8	28.6	63.0	12.4	7.9	4.9	4.6	4.4	14	15	15	2.2	2.2	2.2	19.2	17.6	16.1
BH	Neutral	242.00	258.0	8.7	38.9	28.6	27.1	302.9	36.3	5.3	9.8	8.1	7.2	26	31	28	1.4	2.1	2.2	25.8	19.0	17.9
CHG	Neutral	3.18	3.8	21.7	12.6	31.8	28.1	(33.9)	(60.4)	13.0	4.6	5.1	4.8	35	15	17	5.0	2.2	2.5	8.5	18.1	16.5
RJH	Neutral	27.00	28.0	7.4	7.9	19.2	18.8	1.7	(59.0)	2.0	3.5	3.3	3.2	48	18	17	9.3	3.7	3.8	6.0	12.2	11.6
Average					21.6	29.8	27.1	58.6	(26.8)	9.3	6.0	5.5	5.1	26	18	18	3.0	1.9	2.1	16.2	18.5	16.8

Source: InnovestX Research

Disclaimer

The information in this report has been obtained from sources believed to be reliable. However, its accuracy or completeness is not guaranteed. Any opinions expressed herein reflect our judgment at this date and are subject to change without notice. This report is for information only. It is not to be construed as an offer, or solicitation of an offer to sell or buy any securities. We accept no liability for any loss arising from the use of this document. We or our associates may have an interest in the companies mentioned therein.

InnovestX Securities Company Limited ("INVX") is wholly owned by SCB X Public Company Limited ("SCBX") and The Siam Commercial Bank Public Company Limited ("SCB") is majority-owned by SCBX. Any information related to SCB is for sector comparison purpose.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly-owned by SCB X Public Company Limited ("SCBX"). The Siam Commercial Bank Public Company Limited, which is majority-owned by SCBX, acts as financial advisor of the SCG Chemicals Public Company Limited (SCGC). Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly-owned by SCB X Public Company Limited ("SCBX"). The Siam Commercial Bank Public Company Limited, which is majority-owned by SCBX, acts as financial advisor of the Big C Retail Company Limited (BRC), a subsidiary of Berli Jucker Public Company Limited. Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

This document is prepared by InnovestX Securities Company Limited ("INVX") which is wholly owned by SCB X Public Company Limited ("SCBX"). The Siam Commercial Bank Public Company Limited, which is majority-owned by SCBX, acts as financial advisor of the LH Hotel Leasehold Real Estate Investment Trust. Any opinions, news, research, analyses, prices, statements, forecasts, projections and/or other information contained in this document (the "Information") is provided as general information purposes only and shall not be construed as individualized recommendation of an offer to buy or sell or the solicitation of an offer to buy or sell any securities. INVX and/or its directors, officers and employees shall not be liable for any direct, indirect, incidental, special or consequential loss or damage, resulting from the use of or reliance on the Information, including without limitation to, damages for loss of profits. The investors shall use the Information in association with other information and opinion, including their own judgment in making investment decision. The Information is obtained from sources believed to be reliable, and INVX cannot guarantee the accuracy, completeness and/or correctness of the Information.

INVX reserves the right to modify the Information from time to time without notice and in its sole discretion. This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

Futures and Options trading carry a high level of risk with the potential for substantial losses, and are not suitable for all persons. Before deciding to trade Futures and Options, you should carefully consider your financial position, investment objectives, level of experience, and risk appetite if Futures and Options trading are appropriate. The possibility exists that you could sustain a loss of some or all of your initial investment. You should be aware of all the risks associated with Futures and Options trading, and you are advised to rely on your own judgment while making investment decision and/or should seek advice from professional investment advisor if you have any doubts.

This document is delivered to intended recipient(s) only and is not permitted to reproduce, retransmit, disseminate, sell, distribute, republish, circulate or commercially exploit the Information in any manner without the prior written consent of INVX.

© Copyright 2022 InnovestX Securities Co., Ltd. All right reserved.

CG Rating 2023 Companies with CG Rating

Companies with Excellent CG Scoring

7UP, AAV, ABM, ACE, ACG, ADB, ADD, ADVANC, AEONTS, AF, AGE, AH, AHC, AIRA, AIT, AJ, AKP, AKR, ALLA, ALT, AMA, AMARIN, AMATA, AMATAV, ANAN, AOT, AP, APCO, APCS, ARIP, ARROW, ASEFA, ASK, ASP, ASW, ATP30, AUCT, AWC, AYUD, B, BA, BAFS, BAM, BANPU, BAY, BBGI, BBIK, BBL, BC, BCH, BCP, BCPG, BDMS, BEC, BEM, BEYOND, BGC, BGRIM, BH, BIZ, BJC, BJCHI, BKI, BLA, BOL, BPP, BRI, BROOK, BRR, BTS, BTW, BWG, BYD, CBG, CENTEL, CFRESH, CHASE, CHEWA, CHG, CHOW, CIMBT, CIVIL, CK, CKP, CM, CNT, COLOR, COM7, COTTO, CPALL, CPAXT, CPF, CPI, CPL, CPN, CPW, CRC, CRD, CSC, CSS, CV, DCC, DDD, DELTA, DEMCO, DMT, DOHOME, DRT, DUSIT, EA, EASTW, ECF, ECL, EE, EGCO, EPG, ERW, ETC, ETE, FE, FLOYD, FN, FPI, FPT, FSX, FVC, GBX, GC, GCAP, GENCO, GFPT, GGC, GLAND, GLOBAL, GPSC, GRAMMY, GULF, GUNKUL, HANA, HARN, HENG, HMPRO, HPT, HTC, ICC, ICHI, ICN, III, ILINK, ILM, IMH, IND, INET, INTUCH, IP, IRC, IRPC, ITC, ITEL, IVL, JAS, JTS, KBANK, KCC, KCE, KEX, KKP, KSL, KTB, KTC, KTMS, KUMWEL, KUN, LALIN, LANNA, LH, LHFG, LIT, LOXLEY, LPN, LRH, LST, M, MAJOR, MALEE, MATCH, MBK, MC, M-CHAI, MCOT, MEGA, MFC, MFEC, MILL, MINT, MONO, MOONG, MSC, MST, MTC, MTI, NC, NCH, NCL, NDR, NER, NKI, NOBLE, NRF, NTV, NVD, NWR, NYT, OCC, OISHI¹, ONEE, OR, ORI, OSP, OTO, PAP, PATO, PB, PCSGH, PDG, PDJ, PG, PHOL, PIMO, PJW, PLANB, PLAT, PLUS, PM, POLY, PORT, PPP, PPS, PR9, PRG, PRINC, PRM, PRTR, PSH, PSL, PT, PTC, PTT, PTTEP, PTTGC, Q-CON, QH, QTC, RATCH, RBF, RPH, RS, RT, S, S&J, SA, SABINA, SAK, SAMART, SAMTEL, SAPPE, SAT, SBNEXT, SC, SCB, SCC, SCCC, SCG, SCGP, SCM, SDC, SEAFCO, SEAOL, SECURE, SELIC, SENA, SENX, SFP², SFT, SGC, SGF, SGP, SHR, SICT, SIRI, SIV, SITHAI, SJWD, SKR, SM, SMP, SMT, SNC, SNNP, SNP, SO, SPALI, SPC, SPCG, SPI, SPRC, SR, SSC, SSS, SSSC, STA, STC, STEC, STGT, STI, SUC, SUN, SUSCO, SUTHA, SVR, SVT, SYMC, SYNTEX, SYNTAC, TAE, TCAP, TCMC, TEAMG, TEGH, TFG, TFMAMA, TGE, TGH, THANA, THANI, THCOM, THIP, THRE, THREL, TIDLOR, TIPH, TISCO, TK, TKN, TKS, TKT, TLI, TM, TMC, TMD, TMT, TNDT, TNITY, TNL, TNR, TOA, TOG, TOP, TPBI, TPCS, TPIPL, TPIPP, TPS, TQM, TQR, TRT, TRUE, TRV, TSC, TSTE, TSTH, TTA, TTB, TTCL, TTW, TURTLE, TVDH, TVH, TVO, TVT, TWPC, UAC, UBE, UBIS, UKEM, UP, UPF, UPOIC, UV, VCOM, VGI, VIBHA, VIH, VL, WACOAL, WGE, WHA, WHAUP, WICE, WINMED, WINNER, XPG, YUASA, ZEN

Companies with Very Good CG Scoring

2S, A5, AAI, AIE, ALUCON, AMR, APURE, ARIN, AS, ASIA, ASIAN, ASIMAR, ASN, AURA, BR, BSBM, BTG, CEN, CGH, CH, CHIC, CI, CIG, CMC, COMAN, CSP, DOD, DPAINT, DV8, EFORL, EKH, ESSO, ESTAR, EVER, FORTH, FSMART, FTI, GEL, GPI, HEALTH, HUMAN, IFS, INSET, IT, J, JCKH, JDF, JKN, JMART, JUBILE, K, KCAR, KGI, KIAT, KISS, KK, KTIS, KWC, KWM, LDC, LEO, LHK, MACO, METCO, MICRO, MK, MVP, NCAP, NOVA, NTSC, PACO, PIN, PQS, PREB, PRI, PRIME, PROEN, PROS, PROUD, PSTC, PTECH, PYLON, RCL, SALEE, SANKO, SCI, SCN, SE, SE-ED, SFLEX, SINGER, SKN, SONIC, SORKON, SPVI, SSP, SST, STANLY, STP, SUPER, SVOA, SWC, TCC, TEKA, TFM, TMILL, TNP, TPLAS, TPOLY, TRC, TRU, TRUBB, TSE, VRANDA, WAVE, WFX, WIIK, WIN, WP, XO

Companies with Good CG Scoring

24CS, AMANAH, AMARC, AMC, APP, ASAP, BCT, BE8, BIG, BIOTEC, BLESS, BSM, BVG, CAZ, CCET, CHARAN, CHAYO, CHOTI, CITY, CMAN, CMR, CRANE, CWT, DHOUSE, DTCENT, EASON, FNS, FTE, GIFT, GJS, GTB, GTV, GYT, HL, HTECH, HYDRO, IIG, INGRS, INSURE, IRCP, ITD, ITNS, JCK, JMT, JR, JSP, KBS, KGEN, KJL, L&E, LEE, MASTER, MBAX, MEB, MENA, META, MGT, MITSIB, MJD, MOSHI, MUD, NATION, NNCL, NPK, NSL, NV, OGC, PAF, PCC, PEACE, PICO, PK, PL, PLANET, PLE, PMTA, PPM, PRAKIT, PRAPAT, PRECHA, PRIN, PSG, RABBIT, READY, RJH, RSP, RWI, S11, SAAM, SAF, SAMCO, SAWAD, SCAP, SCP, SIAM, SKE, SKY, SMART, SMD, SMIT, SOLAR, SPA, STECH, STPI, SVR, TC, TCCC³, TEAM, TFI, TIGER, TITL, TKC, TMI, TNH, TPA, TPAC, TRITN, UBA, UMI, UMS, UTP, VARO, VPO, W, WARRIX, WORK, WPH, YONG, ZIGA

Corporate Governance Report

The material contained in this publication is for general information only and is not intended as advice on any of the matters discussed herein. Readers and others should perform their own independent analysis as to the accuracy or completeness or legality of such information. The Thai Institute of Directors, its officers, the authors and editor make no representation or warranty as to the accuracy, completeness or legality of any of the information contained herein. By accepting this document, each recipient agrees that the Thai Institute of Directors Association, its officers, the authors and editor shall not have any liability for any information contained in, or for any omission from, this publication.

The survey result is as of the date appearing in the Corporate Governance Report of Thai Listed Companies. As a result, the survey result may be changed after that date. InnovestX Securities Company Limited does not conform nor certify the accuracy of such survey result.

To recognize well performers, the list of companies attaining "Good", "Very Good" and "Excellent" levels of recognition (Not including listed companies qualified in the "no announcement of the results" clause from 1 January 2022 to 31 October 2023) is publicized.

¹OISHI was voluntarily delisted from the Stock Exchange of Thailand, effectively on September 6, 2023

²SFP was voluntarily delisted from the Stock Exchange of Thailand, effectively on July 19, 2023

³TCCC was voluntarily delisted from the Stock Exchange of Thailand effectively on August 25, 2023

Anti-corruption Progress Indicator

Certified (ได้ผ่านการรับรอง)

2S, 7UP, AAI, ADVANC, AF, AH, AI, AIE, AIRA, AJ, AKP, AMA, AMANAH, AMATA, AMATAV, AP, APCS, AS, ASIAN, ASK, ASP, AWC, AYUD, B, BAFS, BAM, BANPU, BAY, BBGI, BBL, BCH, BCP, BCPG, BE8, BEC, BEYOND, BGC, BGRIM, BKI, BLA, BPP, BROOK, BRR, BSBM, BTS, BWG, CEN, CENTEL, CFRESH, CGH, CHEWA, CHOTI, CHOW, CIG, CIMBT, CM, CMC, COM7, CPALL, CPAXT, CPF, CPI, CPL, CPN, CPW, CRC, CSC, DCC, DELTA, DEMCO, DIMET, DOHOME, DRT, DUSIT, EA, EASTW, ECF, EGCO, EP, EPG, ERW, ESTAR, ETC, ETE, FNS, FPI, FPT, FSMART, FTE, GBX, GC, GCAP, GEL, GFPT, GGC, GJS, GPI, GPSC, GSTEEL, GULF, GUNKUL, HANA, HARN, HENG, HMPRO, HTC, ICC, ICHI, IFS, III, ILINK, ILM, INET, INOX, INSURE, INTUCH, IRPC, ITEL, IVL, JAS, JKN, JR, JTS, KASET, KBANK, KBS, KCAR, KCC, KCE, KGEN, KGI, KKP, KSL, KTB, KTC, L&E, LANNA, LHFG, LHK, LPN, LRH, M, MAJOR, MALEE, MATCH, MBAX, MBK, MC, MCOT, META, MFC, MFEC, MILL, MINT, MONO, MOONG, MSC, MST, MTC, MTI, NATION, NCAP, NEP, NKI, NOBLE, NRF, NWR, OCC, OGC, OR, ORI, PAP, PATO, PB, PCSGH, PDG, PDJ, PG, PHOL, PIMO, PK, PL, PLANB, PLANET, PLAT, PM, PPP, PPPM, PPS, PR9, PREB, PRG, PRINC, PRM, PROS, PSH, PSL, PSTC, PT, PTECH, PTG, PTT, PTTEP, PTTGC, PYLON, Q-CON, QH, QLT, QTC, RABBIT, RATCH, RML, RS, RWI, S&J, SAAM, SABINA, SAK, SAPPE, SAT, SC, SCC, SCCC, SCG, SCGP, SCM, SCN, SEAOL, SE-ED, SELIC, SENA, SGC, SGP, SIRI, SITHAI, SKR, SMIT, SMK, SMP, SNC, SNP, SORKON, SPACK, SPALI, SPC, SPI, SPRC, SRICHA, SSF, SSP, SSSC, SST, STA, STGT, STOWER, SUSCO, SVI, SYMC, SYNTEX, TAE, TAKUNI, TASC, TAPAC, TCMC, TRF, TFI, TFMAMA, TGE, TGH, THANI, THCOM, THIP, THRE, THREL, TIDLOR, TIPCO, TISCO, TKS, TKT, TMD, TMILL, TMT, TNITY, TNL, TNP, TNR, TOG, TOP, TOPP, TPAC, TPC, TSC, TSI, TSTE, TSTH, TTA, TTB, TTCL, TU, TVCS, TVO, TVDH, TUD, UBE, UBIS, UEC, UKEM, UOBKH, UV, VCOM, VGI, VIH, WACOAL, WHA, WHAUP, WICE, WIIK, XO, YUASA, ZEN, ZIGA

Declared (ได้ดำเนินการ)

ACE, ADB, ALT, AMC, ASW, BLAND, BTG, BYD, CAZ, CBG, CV, DEXON, DMT, EKH, FSX, GLOBAL, GREEN, ICN, IHL, ITC, J, JMART, JMT, LEO, LH, MENA, MITSIB, MODERN, NER, NEX, OSP, OTO, PLUS, POLY, PQS, PRIME, PROEN, PRTR, RBF, RT, SA, SANKO, SCB, SENX, SFLEX, SIS, SKE, SM, SVOA, TBN, TEGH, TIPH, TKN, TPAC, TPLAS, TQM, TRUE, W, WPH, XPG

N/A

24CS, 3K-BAT, A, A5, AAV, ABM, ACAP, ACC, ACG, ADD, AEONTS, AFC, AGE, AHC, AIT, AJA, AKR, AKS, ALL, ALLA, ALPHAX, ALUCON, AMARC, AMARIN, AMR, ANAN, ANI, AOT, APCO, APEX, APP, APURE, AQUA, ARIN, ARIP, ARROW, ASAP, ASEFA, ASIA, ASIMAR, ASN, ATP30, AU, AUCT, AURA, B52, BA, BBIK, BC, BCT, BDMS, BEAUTY, BEM, BGT, BH, BIG, BIOTEC, BIS, BIZ, BJC, BJCHI, BKD, BLC, BLESS, BLISS, BM, BOL, BR, BRI, BROCK, BSM, BSRC, BTNC, BTW, BUI, BVG, CCET, CCP, CEYE, CGD, CH, CHARAN, CHASE, CHAYO, CHG, CHIC, CHO, CI, CITY, CIVIL, CK, CKP, CMAN, CMO, CMR, CNT, COCOCO, COLOR, COMAN, CPANEL, CPH, CPR, CPT, CRANE, CRD, CSP, CSR, CSS, CTW, CWT, D, DCON, DDD, DHOUSE, DITTO, DOD, DPAINT, DTCENT, DTCI, DV8, EASON, ECL, EE, EFORL, EMC, ETL, EVER, F&D, FANCY, FE, FLOYD, FMT, FN, FORTH, FTI, FVC, GABLE, GENCO, GFC, GIFT, GL, GLAND, GLOCON, GLORY, GRAMMY, GRAND, GSC, GTB, GTV, GYT, HEALTH, HFT, HL, HPT, HTECH, HUMAN, HYDRO, I2, IFEC, IIG, IMH, IND, INGRS, INSET, IP, IRC, IRCP, IT, ITD, ITNS, ITTHI, JAK, JCK, JCKH, JCT, JDF, JPARK, JSP, JUBILE, K, KAMART, KC, KCG, KCM, KDH, KEX, KIAT, KISS, KJL, KK, KKC, KLINIQ, KOOL, KTIS, KTMS, KUMWEL, KUN, KWC, KWI, KWM, KYE, LALIN, LDC, LEE, LIT, LOXLEY, LPH, LST, MANRIN, MASTER, MATI, MCA, M-CHAI, MCS, MDX, MEB, MEGA, METCO, MGC, MGI, MGT, MICRO, MIDA, MJD, MK, ML, MORE, MOSHI, MTW, MUD, MVP, NAM, NC, NCH, NCL, NDR, NETBAY, NEW, NEWS, NFC, NNCL, NOK, NOVA, NPK, NSL, NTSC, NTV, NUSA, NV, NVD, NYT, OHTL, ONEE, ORN, PACE, PACO, PAF, PCC, PEACE, PERM, PF, PHG, PICO, PIN, PJW, PLE, PLT, PMTA, POLAR, POMPU, PORT, POST, PPM, PRAKIT, PRAPAT, PRECHA, PRI, PRIN, PRO, PROUD, PSG, PSP, PTC, PTL, RAM, RCL, READY, RICHY, RJH, ROCK, ROCTEC, ROH, ROJNA, RP, RPC, RPH, RSP, S, S11, SABUY, SAF, SAFARI, SAFE, SALEE, SAM, SAMART, SAMCO, SAMTEL, SAUCE, SAV, SAWAD, SAWANG, SBNEXT, SCAP, SCGD, SCI, SCL, SCP, SDC, SE, SEAFCO, SECURE, SFT, SGF, SHANG, SHR, SIAM, SICT, SIMAT, SINGER, SINO, SISB, SJWD, SK, SKN, SKY, SLM, SLP, SMART, SMD, SMT, SNNP, SO, SOLAR, SONIC, SPA, SPCG, SPG, SPVI, SQ, SR, SRS, SSC, SSS, STANLY, STARK, STC, STEC, STECH, STHAI, STI, STP, STPI, SUC, SUN, SUPER, SUTHA, SVR, SVT, SWC, SYNEX, TACC, TAN, TAPAC, TC, TCC, TCJ, TCOAT, TEAM, TEAMG, TEKA, TFM, TGPRO, TH, THAI, THANA, THE, THG, THMU, TIGER, TITL, TK, TKC, TLI, TM, TMC, TMI, TMW, TNDT, TNH, TNPC, TOA, TPBI, TPCH, TPIPL, TPIPP, TPL, TPOLY, TPP, TPS, TQR, TR, TRC, TRITN, TRP, TRUBB, TRV, TSE, TTI, TTT, TTW, TURTLE, TVH, TVT, TWP, TWI, TYCN, UAC, UBA, UMI, UMS, UNIQ, UP, UPF, UPOIC, UREKA, UTP, UVAN, VARO, VIBHA, VL, VNG, VPO, VRANDA, WARRIX, WAVE, WFX, WGE, WIN, WINDOW, WINMED, WINNER, WORK, WORLD, WP, YGG, YONG, ZAA

Explanations

Companies participating in Thailand's Private Sector Collective Action Coalition Against Corruption programme (Thai CAC) under Thai Institute of Directors (as of November 1, 2023) are categorised into: companies that have declared their intention to join CAC, and companies certified by CAC.